Abstract Library

#2159 Hepatic Steatosis Secondary to Peptide Receptor Radionuclide Therapy with Somatostatin Analogue

Introduction: Peptide Receptor Radionuclide Therapy (PRRT) with 177-Lutetium-DOTA-TATE is a therapeutic modality for neuroendocrine tumors. It has some well known side effects, concerning specially the bone marrow (from cytopenias to myelodysplastic syndrome), in addition to mild renal effects. Hepatotoxicity from PRRT is still being studied.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Matheos de Lima B

Authors: Arruda Matheos de Lima B, Gonçalves R, Romano Gaspar P, Linhares Riello de Mello E, Oliveira Albagli R,

Keywords: peptide receptor radionuclide therapy, lutetium, collateral effects, hepatotoxicity, neuroendocrine tumor, hepatic steatosis,

#1720 Yttrium90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor and accounts for 5-10% of all thyroid cancers. Distant metastases frequently involve the liver and patient’s survival after diagnosis is around 20% at 10 years

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marques B

Authors: Marques B, Martins R, Gonçalves B, Sousa M, Violante L,

Keywords: neuroendocrine, yttrium radioisotopes,

#1717 Yttrium-90 Radioembolization for Progressive Medullary Thyroid Carcinoma with Exclusive Liver Metastasis

Introduction: Medullary thyroid carcinoma (MTC) is a well-differentiated neuroendocrine tumor and accounts for 5-10% of all thyroid cancers. Distant metastases frequently involve the liver and patient’s survival after diagnosis is around 20% at 10 years

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Marques B

Authors: Marques B, Martins R, Gonçalves B, Sousa M, Violante L,

Keywords: neuroendocrine, yttrium radioisotopes,